Results

1–10 of 12 results for AAV

Preclinical Evaluation of BGTF-027 (AAV.7m8-L-opsin), a Novel Intravitreal Gene Therapy for the Treatment of Blue Cone Monochromacy
Szilárd Kiss, MD
Annual Meeting Talks
2024
Pooled Safety Analysis and Immunogenicity of a Single Intravitreal Injection of JNJ-1887 (Gene Therapy, AAVCAGsCD59) in Patients With AMD
Christine Kay, MD
Annual Meeting Talks
2024
Safety and Durability of Voretigene Neparvovec for Biallelic RPE65-Mediated Inherited Retinal Disease: Phase 3 Results at 8 Years and 9 Years
Stephen R. Russell, MD
Annual Meeting Talks
2024
Interim Subretinal Gene Therapy Safety Results in Two Phase 1/2 Open-label, Dose-Escalation Clinical Trials to Treat Achromatopsia
Lejla Vajzovic, MD, FASRS
Annual Meeting Talks
2022
Biodistribution of Suprachoroidal Drug and Viral Vector Delivery Across Animal Models and Human Trials
Glenn C. Yiu, MD, PhD
Annual Meeting Talks
2022
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Annual Meeting Talks
2021
Preliminary Results from a First-in-human Phase I/II Gene Therapy Study (FOCUS) of Subretinally Delivered GT005, an Investigational AAV2 Vector, in Patients with Geographic Atrophy Secondary to Age-related Macular Degeneration
Jared S. Nielsen, MD, MBA
Updates from the Field
2022
AAV-RPGR Gene Therapy for RPGR-Associated X-Linked Retinitis Pigmentosa: 6-month Results From a Phase 1/2 Clinical Trial
Michel Michaelides, BSc, MB BS, MD(Res), FRCOphth, FACS
Annual Meeting Talks
2020
Intravitreal AAVCAGsCD59 as Adjunct Anti-VEGF Treatment for Wet Age-Related Macular Degeneration
Jeffrey S. Heier, MD
Annual Meeting Talks
2020
Suprachoroidal Delivery of RGX-314 for Neovascular AMD: Initial Results From the Phase II AAVIATE Study
Mark R. Barakat, MD
Updates from the Field
2021